MRI is the standard of care for most neuroimaging indications, and advanced sequences are providing an ever-growing ability for lesion characterisation. PET is widely used in oncology, and the limitations of Fluorine-18 fluorodeoxyglucose in neuro-oncology have been overcome by the development of novel PET tracers. The sequential use of these modalities harnesses the strengths of both, and has led to the development of combined PET-MR systems. This educational exhibit demonstrates the ways in which MRI and PET can be used in a complementary manner for improved lesion characterisation in neuro-oncology, including diagnosis and treatment planning.
This abstract and the presentation materials are available to members only; a login is required.